Novavax Inc.
NVAX | NASDAQ
$10.41
+$0.30 (+2.97%)
At close: Sep 21, 2026, 4:00 PM ET
$10.50
+$0.09 (+0.86%)
Pre-market:
Sep 22, 2026, 9:06 AM ET
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 1.12B | 682.16M | 556.38M | 1.6B | 197.58M | 22.39M |
Cost of Revenue | 71.14M | 202.74M | 343.77M | 902.64M | n/a | n/a |
Gross Profit | 1.05B | 479.42M | 212.61M | 696.31M | 197.58M | 22.39M |
Operating Income | 563.27M | -248.93M | -566.51M | -644.74M | -1.69B | -416.72M |
Interest Income | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | 442.17M | -176.62M | -543.03M | -653.65M | -1.71B | -418.26M |
Net Income | 440.3M | -187.5M | -545.06M | -657.94M | -1.74B | -418.26M |
Selling & General & Admin | 150.35M | 337.19M | 468.95M | 488.69M | 298.36M | 145.29M |
Research & Development | 336.82M | 391.17M | 737.5M | 1.24B | 2.53B | 747.03M |
Other Expenses | 1.9M | n/a | -427.32M | -382.92M | -948.71M | -453.21M |
Operating Expenses | 489.07M | 728.35M | 779.13M | 1.34B | 1.88B | 439.11M |
Interest Expense | 22.55M | 20.08M | 14.42M | 19.88M | 21.13M | 15.15M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 560.21M | 931.09M | 1.12B | 2.24B | 1.88B | 439.11M |
Income Tax Expense | 1.87M | 10.88M | 2.03M | 4.29M | 29.22M | n/a |
Shares Outstanding (Basic) | 161.99M | 152.19M | 100.77M | 78.18M | 74.4M | 57.55M |
Shares Outstanding (Diluted) | 173.1M | 152.19M | 100.77M | 78.18M | 74.4M | 57.55M |
EPS (Basic) | 2.72 | -1.23 | -5.41 | -8.42 | -23.44 | -7.43 |
EPS (Diluted) | 2.54 | -1.23 | -5.41 | -8.42 | -23.44 | -7.43 |
EBITDA | 492.33M | -108.04M | -487.39M | -604.71M | -1.68B | -398.23M |
EBIT | 464.71M | -156.54M | -528.62M | -633.77M | -1.69B | -403.11M |
Depreciation & Amortization | 27.61M | 48.5M | 41.23M | 29.05M | 12.66M | 4.89M |
Add to Watchlist
Select watchlists to add or remove NVAX